Search results for " Cardiovascular disease"

showing 10 items of 179 documents

Impact of a Mediterranean Dietary Pattern and Its Components on Cardiovascular Risk Factors, Glucose Control, and Body Weight in People with Type 2 D…

2018

This study evaluates the relation of a Mediterranean dietary pattern and its individual components with the cardiovascular risk factors profile, plasma glucose and body mass index (BMI) in people with type 2 diabetes. We studied 2568 participants at 57 diabetes clinics. Diet was assessed with the EPIC (European Prospective Investigation into Cancer and Nutrition) questionnaire, adherence to the Mediterranean diet was evaluated with the relative Mediterranean diet score (rMED). A high compared to a low score was associated with a better quality of diet and a greater adherence to the nutritional recommendations for diabetes. However, even in the group achieving a high score, only a small prop…

Blood GlucoseMaleMediterranean diet; cardiovascular risk; diabetes; glucose control; plasma lipids; relative Mediterranean diet score; Aged; Biomarkers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus Type 2; Female; Glycated Hemoglobin A; Humans; Lipids; Male; Middle Aged; Nutritive Value; Patient Compliance; Protective Factors; Recommended Dietary Allowances; Risk Factors; Body Mass Index; Diet Healthy; Diet Mediterranean; Feeding BehaviorGlycated Hemoglobin AMediterranean dietRecommended Dietary AllowanceCross-sectional studyHealthy DietSaturated fatBlood PressureType 2 diabetes030204 cardiovascular system & hematologyMediterraneanDiet MediterraneanDiabeteRecommended Dietary AllowancesSettore MED/13 - EndocrinologiaBody Mass Indexchemistry.chemical_compound0302 clinical medicineRisk FactorsCardiovascular Disease030212 general & internal medicineNutrition and DieteticsdiabetesLipidMiddle AgedLipidsEuropean Prospective Investigation into Cancer and NutritionCardiovascular DiseasesFemaleDiet Healthylcsh:Nutrition. Foods and food supplyNutritive ValueType 2Humancardiovascular riskCardiovascular risk; Diabetes; Glucose control; Mediterranean diet; Plasma lipids; Relative mediterranean diet score; Aged; Biomarkers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus Type 2; Female; Glycated Hemoglobin A; Humans; Lipids; Male; Middle Aged; Nutritive Value; Patient Compliance; Protective Factors; Recommended Dietary Allowances; Risk Factors; Body Mass Index; Diet Mediterranean; Feeding Behavior; Healthy Diet; Food Science; Nutrition and DieteticsPlasma lipidlcsh:TX341-641Article03 medical and health sciencesEnvironmental healthDiabetes mellitusMediterranean dietplasma lipidsmedicineDiabetes MellitusHumansProtective FactorAgedCross-Sectional StudieGlycated Hemoglobinglucose controlHealthybusiness.industryRisk FactorBiomarkerFeeding Behaviorrelative Mediterranean diet scoreProtective Factorsmedicine.diseaseDietCross-Sectional StudieschemistryDiabetes Mellitus Type 2Patient ComplianceGlycated hemoglobinbusinessBody mass indexBiomarkersFood Science
researchProduct

Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis: Results from a cross-sectional study.

2017

Abstract Although the better management of rheumatoid arthritis (RA) has significantly improved the long-term outcome of affected patients, a significant proportion of these may develop associated comorbidities including cardiometabolic complications. However, it must be pointed out that a comprehensive cardiometabolic evaluation is still poorly integrated into the management of RA patients, due to a limited awareness of the problem, a lack of appropriate clinical studies, and optimal strategies for cardiovascular (CV) risk reduction in RA. In addition, although several studies investigated the possible association between traditional CV risk factors and RA, conflicting results are still av…

Blood GlucoseMalerheumatoid arthritisTime FactorsCross-sectional studyType 2 diabetesAdrenal Cortex HormoneBody Mass IndexArthritis Rheumatoid0302 clinical medicineimpaired fasting glucoseAdrenal Cortex HormonesRisk FactorsRheumatoidCardiovascular DiseasePrevalence030212 general & internal medicineMedicine (all)Diabetes MellituGeneral MedicineMiddle AgedC-Reactive ProteinCholesterolcardiovascular risk; impaired fasting glucose; inflammation; rheumatoid arthritis; type 2 diabetes;Cardiovascular DiseasesCohortHypertensionFemaletype 2 diabetesCase-Control Studiecardiovascular risk; impaired fasting glucose; inflammation; rheumatoid arthritis; type 2 diabetes; Adrenal Cortex Hormones; Adult; Aged; Arthritis Rheumatoid; Blood Glucose; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Case-Control Studies; Cholesterol; Cross-Sectional Studies; Diabetes Mellitus Type 2; Female; Glucose Intolerance; Humans; Hypertension; Male; Middle Aged; Prevalence; Risk Factors; Time Factors; Medicine (all)Type 2Research ArticleArthritiHumanAdultcardiovascular riskmedicine.medical_specialtyTime FactorObservational StudyNO03 medical and health sciencesInternal medicineDiabetes mellitusGlucose Intolerancemedicinecardiovascular risk impaired fasting glucose inflammation rheumatoid arthritis type 2 diabetesHumansAged030203 arthritis & rheumatologyCross-Sectional Studietype 2 diabetebusiness.industryRisk Factor6900Case-control studyrheumatoid arthritimedicine.diseaseImpaired fasting glucoseSettore MED/16 - ReumatologiaCross-Sectional StudiesDiabetes Mellitus Type 2inflammationCase-Control StudiesMetabolic syndromebusinessBody mass index
researchProduct

Unrecognised cardiovascular disease in type 2 diabetes: is it time to act earlier?

2018

Abstract Cardiovascular disease (CVD) is the most significant prognostic factor in individuals with type 2 diabetes (T2D). However, a significant number of individuals may develop CVD that does not present with the classic angina-related or heart failure symptoms. In these cases, CVD may seem to be ‘silent’ or ‘asymptomatic’, but may be more accurately characterised as unrecognised diabetic cardiac impairment. An initial step to raise awareness of unrecognised CVD in individuals with T2D would be to reach a consensus regarding the terminology used to describe this phenomenon. By standardising the terminologies, and agreeing on the implementation of an efficient screening program, it is anti…

Blood Glucoselcsh:Diseases of the circulatory (Cardiovascular) systemEndocrinology Diabetes and Metabolism10265 Clinic for Endocrinology and DiabetologyDiseaseType 2 diabetes030204 cardiovascular system & hematologySilent0302 clinical medicineRisk FactorsMass ScreeningAsymptomatic ; Atypical ; Cardiovascular disease ; Screening ; Silent ; Type 2 diabetes ; Unrecognised.Type 2 diabetesCardiovascular diseasePrognosisAsymptomatic3. Good health2712 Endocrinology Diabetes and MetabolismCardiovascular DiseasesScreeningmedicine.symptomCardiology and Cardiovascular Medicinemedicine.medical_specialtyPrognostic factor030209 endocrinology & metabolism610 Medicine & healthRisk AssessmentAsymptomatic2705 Cardiology and Cardiovascular Medicine03 medical and health sciencesPredictive Value of TestsInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsIntensive care medicineUnrecognisedbusiness.industrymedicine.diseaseEarly DiagnosisDiabetes Mellitus Type 2lcsh:RC666-7012724 Internal MedicineHeart failureAsymptomatic DiseasesCommentarybusinessAtypicalBiomarkers
researchProduct

Hydroxychloroquine, COVID ‐19 and diabetes. Why it is a different story

2020

Hydroxychloroquine has been proposed for the cure of the COVID-19 due to its anti-inflammatory and anti-viral action. People with diabetes are more prone to severe outcome if affected by COVID-19 and the use of Hydroxychloroquine might have some benefit in this setting. However, the use of Hydroxychloroquine in diabetes deserves particular attention for its documented hypoglycemic action.

Blood Glucosemedicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Endocrinology Diabetes and MetabolismSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MEDLINE030209 endocrinology & metabolismGlycemic Control030204 cardiovascular system & hematologySeverity of Illness IndexDiabetes Complications03 medical and health sciences0302 clinical medicineEndocrinologyCommentariesInternal medicineDiabetes mellitusSeverity of illnessDiabetes MellitusInternal MedicinemedicineHyperglycaemiaHumansHypoglycemic AgentsBlood Glucose COVID-19 Diabetes Complications Diabetes Mellitus Glycemic Control Humans Hydroxychloroquine Hypoglycemic Agents SARS-CoV-2 Severity of Illness Index Signal TransductionSARS-CoV-2business.industryDiabetesCOVID-19Hydroxychloroquinemedicine.diseaseCOVID-19 Drug TreatmentACE2 Cardiovascular disease COVID‐19CommentarybusinessHydroxychloroquineSignal Transductionmedicine.drugDiabetes/Metabolism Research and Reviews
researchProduct

Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strat…

2021

Abstract Recent advances in human genetics, together with a large body of epidemiologic, preclinical, and clinical trial results, provide strong support for a causal association between triglycerides (TG), TG-rich lipoproteins (TRL), and TRL remnants, and increased risk of myocardial infarction, ischaemic stroke, and aortic valve stenosis. These data also indicate that TRL and their remnants may contribute significantly to residual cardiovascular risk in patients on optimized low-density lipoprotein (LDL)-lowering therapy. This statement critically appraises current understanding of the structure, function, and metabolism of TRL, and their pathophysiological role in atherosclerotic cardiova…

CHOLESTERYL ESTER TRANSFERTO-MODERATE HYPERTRIGLYCERIDEMIALipoprotein remnants030204 cardiovascular system & hematologyBioinformaticsResidual riskBrain Ischemiachemistry.chemical_compoundVoeding Metabolisme en Genomica0302 clinical medicineIschaemic strokeAcademicSubjects/MED00200Myocardial infarctionLOW-GRADE INFLAMMATIONALL-CAUSE MORTALITY[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism0303 health sciencesAtherosclerotic cardiovascular diseasedigestive oral and skin physiology[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismCardiovascular diseaseMetabolism and Genomics3. Good healthStrokeLOW-DENSITY LIPOPROTEINSCardiovascular DiseasesMetabolisme en GenomicaCORONARY-ARTERY-DISEASENutrition Metabolism and GenomicsCardiology and Cardiovascular MedicineB-CONTAINING LIPOPROTEINSLipoproteinsTriglyceride-rich lipoproteinsHEART-DISEASE03 medical and health sciencesSpecial ArticleVoedingmedicineHumansHOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIATriglycerides030304 developmental biologyNutritionVLAGTriglyceridebusiness.industryAPO-Bmedicine.diseaseAtherosclerosisResidual riskIncreased riskchemistry3121 General medicine internal medicine and other clinical medicineEuropean atherosclerosis societybusinessLipoprotein
researchProduct

Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

2015

Statins are one of the most commonly prescribed drugs in clinical practice. They are usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy are muscle-related. The recent statement of the European Atherosclerosis Society (EAS) has focused on statin-associated muscle symptoms (SAMS), and avoided the use of the term 'statin intolerance'. Although muscle syndromes are the most common adverse effects observed after statin therapy, excluding other side effects might underestimate the number of patients with statin intolerance, which might be observed in 10 - 15% of patients. In clinical practice, statin intolerance limits effecti…

CHRONIC KIDNEY-DISEASERANDOMIZED CONTROLLED-TRIALSMuscle symptomPLACEBO-CONTROLLED TRIALMedicine General & InternalMuscular DiseasesCardiovascular DiseaseGeneral & Internal MedicineDefinition; Muscle symptoms; Risk factors; Statin intolerance; Cardiovascular Diseases; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Pharmacology (medical); Medicine (all)Humansdefinitionrisk factorsPharmacology (medical)CORONARY-HEART-DISEASETHROMBOTIC THROMBOCYTOPENIC PURPURAcardiovascular diseasesFATTY LIVER-DISEASEDyslipidemiasPRIMARY BILIARY-CIRRHOSISScience & TechnologyMuscular DiseasePOST-HOC ANALYSISMedicine (all)nutritional and metabolic diseases1103 Clinical SciencesCOA-REDUCTASE INHIBITORSDyslipidemiaDENSITY-LIPOPROTEIN CHOLESTEROLCardiovascular Diseasesmuscle symptomslipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorRisk factorPosition PaperHydroxymethylglutaryl-CoA Reductase InhibitorsLife Sciences & BiomedicineHumanstatin intoleranceArchives of Medical Science : AMS
researchProduct

Current and emerging drugs for the treatment of atherosclerosis: the evidence to date

2022

Introduction: Atherosclerosis can be considered a chronic inflammatory process that stands out as a dominant cause of cardiovascular disease (CVD). Since blood lipids are the leading risk factor for atherosclerosis development, lowering low-density lipoprotein cholesterol (LDL-C) and other apolipoprotein B-containing lipoproteins reduces the risk of future cardiovascular events. However, there has been significant progress in developing lipid-lowering drugs for aggressive management of dyslipidemia, the rates of CVD events remain unacceptably high, so there is great need to identify novel therapeutic pathways targeting the atherosclerosis process.Areas covered: We discussed the current guid…

Cardiovascular DiseasesInternal MedicineHumansCholesterol LDLAtherosclerosis cardiovascular disease inflammation oxidative stress preventionGeneral MedicineAtherosclerosisOxidantsCardiology and Cardiovascular MedicineLipidsDyslipidemiasExpert Review of Cardiovascular Therapy
researchProduct

Polyvascular subclinical atherosclerosis in familial hypercholesterolemia: The role of cholesterol burden and gender

2019

International audience; BACKGROUND AND AIM:Heterozygous familial hypercholesterolemia (HeFH) is a genetic disease characterized by a heterogeneous phenotype. The assessment of cardiovascular (CV) risk is challenging for HeFH. Cholesterol burden (CB) allows to estimate the lifelong exposure to high levels of cholesterol. The aim of this study was to analyze the distribution of subclinical atherosclerosis and the relationship between atherosclerosis and the CB in a sample of HeFH patients, focusing on sex-related differences.METHODS AND RESULTS:154 asymptomatic HeFH subjects underwent coronary-artery-calcium score (CACs) and Doppler ultrasound of carotid and femoral arteries. Yearly lipid pro…

Carotid Artery DiseasesMaleCarotid atherosclerosisPeripheral arterial atherosclerosisTime Factors[SDV]Life Sciences [q-bio]Endocrinology Diabetes and MetabolismMedicine (miscellaneous)Coronary Artery DiseaseDiseaseFamilial hypercholesterolemia030204 cardiovascular system & hematologySeverity of Illness Indexchemistry.chemical_compound0302 clinical medicineRisk FactorsAtherosclerosis; Calcium score; Cardiovascular disease; Cardiovascular risk; Cholesterol burden; Coronary artery calcium; Familial hypercholesterolemia; Peripheral arterial atherosclerosis; Adult; Aged; Asymptomatic Diseases; Biomarkers; Carotid Artery Diseases; Cholesterol; Coronary Artery Disease; Cross-Sectional Studies; Female; Femoral Artery; Genetic Predisposition to Disease; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Paris; Peripheral Arterial Disease; Phenotype; Prevalence; Prognosis; Risk Assessment; Risk Factors; Severity of Illness Index; Sex Factors; Time Factors; Young AdultPrevalenceMedicineNutrition and Dietetics[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismMiddle AgedPrognosisCardiovascular diseaseCalcium score3. Good healthFemoral ArteryCholesterol burdenCholesterolPhenotypeAtherosclerosiCardiologyPopulation studyFemalemedicine.symptomCardiology and Cardiovascular MedicineAdultParismedicine.medical_specialtyFamilial hypercholesterolemia030209 endocrinology & metabolismRisk AssessmentAsymptomaticCoronary artery calciumHigh cholesterolHyperlipoproteinemia Type IIPeripheral Arterial DiseaseYoung Adult03 medical and health sciencesSex Factors[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicineHumansGenetic Predisposition to DiseaseAgedbusiness.industryCholesterolAtherosclerosismedicine.diseaseCardiovascular riskCross-Sectional StudieschemistrySubclinical atherosclerosisAsymptomatic DiseasesbusinessBiomarkers
researchProduct

High plasma levels of endothelin-1 enhance the predictive value of preclinical atherosclerosis for future cerebrovascular and cardiovascular events: …

2014

BACKGROUND AND PURPOSE: Clinical and experimental evidence suggests that endothelin-1 (Et-1) plays a role in cardiac and vascular disease. In the present study, we investigated the prognostic significance of Et-1 for cerebrovascular and cardiovascular outcome, in a 20-year follow-up. METHODS: We studied 82 originally healthy individuals, referred to our Unit of Cardiovascular Prevention, to evaluate the presence of asymptomatic carotid lesions. We subdivided these individuals into two groups, according to the plasma values of Et-1 (respectively ≤ or >2.7 pg/ml). Traditional cardiovascular risk factors were investigated, and by carotid ultrasound examination, we distinguished between normal …

Carotid Artery DiseasesMalePredictive Value of TestCarotid Intima-Media ThicknessRisk FactorsCardiovascular Diseasefollow-upProspective Studiescardiovascular events; cerebrovascular events; endothelin-1; follow-up; Adult; Aged; Asymptomatic Diseases; Biomarkers; Cardiovascular Diseases; Carotid Artery Diseases; Carotid Intima-Media Thickness; Cerebrovascular Disorders; Endothelin-1; Female; Follow-Up Studies; Humans; Male; Middle Aged; Plaque Atherosclerotic; Predictive Value of Tests; Prognosis; Prospective Studies; Risk Factors; Cardiology and Cardiovascular Medicine; Medicine (all)Prospective cohort studyEndothelin-1Medicine (all)Follow up studiesGeneral MedicineMiddle AgedPrognosiscardiovascular eventPredictive valuePlaque AtheroscleroticCardiovascular DiseasesPredictive value of testsCerebrovascular DisorderCardiologyFemaleCardiology and Cardiovascular MedicineHumanAdultmedicine.medical_specialtyPrognosicerebrovascular eventFollow-Up StudiePredictive Value of TestsCarotid Intima-Media ThickneInternal medicinemedicineHumansAsymptomatic DiseasesAgedAsymptomatic DiseaseCarotid Artery Diseasebusiness.industryVascular diseaseRisk FactorBiomarkermedicine.diseaseEndothelin 1Settore MED/11 - Malattie Dell'Apparato CardiovascolareProspective StudieCerebrovascular DisordersHigh plasmaAsymptomatic DiseasesbusinessBiomarkersFollow-Up Studies
researchProduct

Physical inactivity and cardiovascular disease at the time of coronavirus disease 2019 (COVID-19).

2020

China2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)EpidemiologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Confronting the reality of COVIDPneumonia ViralDiseaselaw.inventionBetacoronaviruslawCommentariesCardiovascular DiseaseQuarantineMedicineHumansLife StylePandemicsbiologybusiness.industrySARS-CoV-2Physical Inactivity Cardiovascular Disease COVID-19COVID-19Sedentary behaviorbiology.organism_classificationVirologyCoronavirusEditorialCardiovascular DiseasesQuarantineSedentary BehaviorCardiology and Cardiovascular MedicinebusinessPhysical InactivityCoronavirus InfectionsBetacoronavirusEuropean journal of preventive cardiology
researchProduct